Kemper C - Search Results

1

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.

Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, Witt M, Diamond C, Haubrich R, Louie S; California Collaborative Treatment Group 578 Team. Goicoechea M, et al. Among authors: kemper c. J Infect Dis. 2008 Jan 1;197(1):102-8. doi: 10.1086/524061. J Infect Dis. 2008. PMID: 18171292 Clinical Trial.

2

A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients.

Best BM, Goicoechea M, Witt MD, Miller L, Daar ES, Diamond C, Tilles JG, Kemper CA, Larsen R, Holland DT, Sun S, Jain S, Wagner G, Capparelli EV, McCutchan JA, Haubrich RH; California Collaborative Treatment Group 578 Study Team. Best BM, et al. Among authors: kemper ca. J Acquir Immune Defic Syndr. 2007 Dec 1;46(4):433-42. doi: 10.1097/QAI.0b013e318156f029. J Acquir Immune Defic Syndr. 2007. PMID: 17786128 Clinical Trial.

3

Abacavir and tenofovir disoproxil fumarate co-administration results in a nonadditive antiviral effect in HIV-1-infected patients.

Goicoechea M, Jain S, Bi L, Kemper C, Daar ES, Diamond C, Ha B, Flaherty J, Sun S, Richman D, Louie S, Haubrich R; California Collaborative Treatment Group. Goicoechea M, et al. Among authors: kemper c. AIDS. 2010 Mar 13;24(5):707-16. doi: 10.1097/QAD.0b013e32833676eb. AIDS. 2010. PMID: 20087154 Clinical Trial.

4

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group. Haubrich RH, et al. AIDS. 2002 Oct 18;16(15):F33-40. doi: 10.1097/00002030-200210180-00001. AIDS. 2002. PMID: 12370520 Clinical Trial.

5

A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD; California Collaborative Treatment Group. Haubrich RH, et al. AIDS. 2005 Feb 18;19(3):295-302. AIDS. 2005. PMID: 15718840 Clinical Trial.

6

A computer-based system to aid in the interpretation of plasma concentrations of antiretrovirals for therapeutic drug monitoring.

Goicoechea M, Vidal A, Capparelli E, Rigby A, Kemper C, Diamond C, Witt MD, Haubrich R; California Collaborative Treatment Group. Goicoechea M, et al. Among authors: kemper c. Antivir Ther. 2007;12(1):55-62. Antivir Ther. 2007. PMID: 17503748 Clinical Trial.

7

Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors.

Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R; California Collaborative Treatment Group #575 Team. Kemper CA, et al. AIDS. 2001 Mar 30;15(5):609-15. doi: 10.1097/00002030-200103300-00010. AIDS. 2001. PMID: 11316998

8

Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial.

Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, Deresinski SC; California Collaborative Treatment Group. Kemper CA, et al. J Infect Dis. 2003 Apr 15;187(8):1327-31. doi: 10.1086/374562. Epub 2003 Mar 24. J Infect Dis. 2003. PMID: 12696015 Clinical Trial.

9

The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients.

Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH; California Collaborative Treatment Group. Yasuda JM, et al. Among authors: kemper ca. Antivir Ther. 2004 Oct;9(5):753-61. Antivir Ther. 2004. PMID: 15535413 Clinical Trial.

10

Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.

Karris MY, Jain S, Bowman VQ, Rieg G, Goicoechea M, Dube MP, Kerkar S, Kemper C, Diamond C, Sun X, Daar ES, Haubrich RH, Morris S; California Collaborative Treatment Group (CCTG) 589 Study Team. Karris MY, et al. Among authors: kemper c. J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e48-50. doi: 10.1097/QAI.0000000000000990. J Acquir Immune Defic Syndr. 2016. PMID: 26977746 Free PMC article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

292 results

Search Page

Filters